Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Dynamk Capital is a New York-based venture capital firm specializing in the life sciences sector. Founded to support entrepreneurs in the biopharmaceutical industry, it focuses on providing essential technologies and services. The firm has backed six companies to date.
Dynamk Capital invests in life sciences startups, particularly those offering technologies and services to the biopharma sector. Their investment thesis emphasizes biotechnology, cell and gene therapies, vaccines, and regenerative medicine, targeting early-stage companies that align with these areas.
Notable companies in Dynamk Capital's portfolio include bit.bio, which provides human cells for research and therapy; Alpenglow Biosciences, known for 3D imaging solutions; Curi Bio, a preclinical discovery platform; CellFE Biotech, focused on gene-editing payloads; Bionter AG, offering analytical testing solutions; and RoosterBio, which specializes in large-scale cell therapy production.
Submit your pitch through their website's contact form for consideration.
Dynamk Capital primarily invests in seed to Series A stages, focusing on early-stage life sciences startups.
The firm typically invests in amounts that align with the needs of early-stage companies in the life sciences sector, though specific figures are not disclosed.
Yes, Dynamk Capital often takes the lead in investment rounds, particularly when they find a strong alignment with their focus areas.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.